Literature DB >> 6813497

Pharmacokinetics of auranofin in animals.

A P Intoccia, T L Flanagan, D T Walz, L Gutzait, J E Swagzdis, J Flagiello, B Y Hwang, R H Dewey, H Noguchi.   

Abstract

Gold from orally administered auranofin (AF) was absorbed 17-23% in rats and 15-38% in dogs. Gold was highly bound to blood cells and plasma proteins. Gold terminal half life was 1.2-1.8 days in rat blood and plasma (measured for 7 days post dose) and 19.5 days in the dog (measured for 42 days). Excretion of gold (rat and dog) was via feces (84 and 81%) urine (10 and 16%) and bile (3% of dose). Rat tissue levels of gold were highest in the kidney. Evidence indicated that AF was rapidly degraded to triethylphosphine oxide with the remaining molecular fragments postulated to be a protein-gold complex and acetylthioglucose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813497

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  6 in total

Review 1.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 2.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  Progress in the characterization of gold drugs.

Authors:  M C Grootveld; M T Razi; P J Sadler
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

4.  Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST).

Authors:  D E Furst; S H Dromgoole
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

5.  Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.

Authors:  Marcel Kaiser; Pascal Mäser; Leela Pavan Tadoori; Jean-Robert Ioset; Reto Brun
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

6.  Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.

Authors:  Lauren Fernandez-Vega; Valeria A Ruiz Silva; Tania M Domínguez-González; Sebastián Claudio-Betancourt; Rafael E Toro-Maldonado; Luisa C Capre Maso; Karina Sanabria Ortiz; Jean A Pérez-Verdejo; Janeishly Román González; Grecia T Rosado-Fraticelli; Fabiola Pagán Meléndez; Fabiola M Betancourt Santiago; Daniel A Rivera-Rivera; Carlos Martínez Navarro; Andrea C Bruno Chardón; Axel O Vera; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2020-01-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.